Progesterone (progesterone)
Progestins Intramuscular Vial (Ml); Oral Capsule; Vaginal Insert
Last reviewed · Source: First Databank (FDB) drug data
Overview
Progesterone is a naturally occurring progestin secreted by the corpus luteum and is the prototype of the progestins.
Progesterone is used orally to reduce the incidence of endometrial hyperplasia in postmenopausal women receiving estrogen replacement therapy.
Generic name: progesterone
Pronunciation: (pro-JESS-ter-own)
Drug class: Progestins
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Progesterone
Indications
The following indications are listed for Progesterone:
- Abnormal Uterine Bleeding Due To Hormonal Imbalance
- Amenorrhea Secondary To Ovarian Dysfunction
Also known as: Abnormal Uterine Bleeding Secondary To Hormone Imbalance.
Dosing
No dosing information is available for this tab.
Progesterone is administered by orally, intravaginally, and by IM injection.
Progesterone capsules are administered orally once daily at bedtime. Women who have difficulty swallowing the capsules should be advised to swallow progesterone capsules while in an upright position and with adequate amounts of fluid (e.g., a glass of water). Administration at bedtime may alleviate some of the adverse effects (e.g., dizziness, blurred vision) associated with the drug.
Progesterone vaginal gel should not be administered concurrently with other intravaginal preparations. If therapy with another agent administered intravaginally is needed, such therapy should be administered 6 hours before or 6 hours after progesterone vaginal gel.
Concomitant use of progesterone vaginal inserts with other preparations that are administered intravaginally is not recommended. Although specific studies have not been undertaken, the possibility exists that concomitant administration of a progesterone vaginal insert with another preparation administered intravaginally may alter the release and absorption of progesterone from the vaginal insert.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Progesterone 100 Mg Vag Insert | Maintenance | Insert 1 vaginal insert (100 mg) by vaginal route 2 times per day. |
| Progesterone 500 Mg/10 Ml Vial | Maintenance | Inject 0.1 milliliter (5 mg) by intramuscular route once daily. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Progesterone 500 Mg/10 Ml Vial | Maintenance | Inject 0.1 milliliter (5 mg) by intramuscular route once daily. |
| Progesterone 100 Mg Vag Insert | Maintenance | Insert 1 vaginal insert (100 mg) by vaginal route 2 times per day. |
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Progestin Replacement Therapy/Ulipristal
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Ulipristal is a progesterone receptor modulator and binds to the progesterone receptor with high affinity.(1)(2)
CLINICAL EFFECTS: Concurrent use of ulipristal may make progesterone products ineffective.(1,2) These agents may also make ulipristal ineffective.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Products containing progestin should not be used within 12 days of ulipristal discontinuation.(3)
DISCUSSION: Ulipristal is a progesterone receptor modulator and binds to the progesterone receptor with high affinity, thus it may interfere with the efficacy of progestin products.(1-3) These products may also make ulipristal ineffective.(3)
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Carcinoma of breast
- Cerebrovascular accident
- Disease of liver
- Malignant neoplasm of liver
- Porphyria
- Pulmonary thromboembolism
- Thromboembolic disorder
- Acute myocardial infarction
- Bed-ridden
- Cerebrovascular accident
- Coronary artery disease
- Deep venous thrombosis
- Disease of liver
- Migraine
- Neoplasm of liver
- Obesity
- Predisposition to thrombosis
- Pulmonary thromboembolism
- Retinal thrombosis
- Thromboembolic disorder
- Thrombophlebitis
- Tobacco smoker
- Asthma
- Chronic heart failure
- Depression
- Diabetes mellitus
- Edema
- Hyperlipidemia
- Hypertension
- Kidney disease with reduction in glomerular filtration rate (GFr)
- Migraine
- Seizure disorder
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Abdominal distension
- Abnormal vaginal bleeding
- Abnormal vaginal bleeding
- Irregular menstrual periods
- Irregular menstrual periods
Less Frequent
- Endometrial hyperplasia
- Hypersensitivity drug reaction
- Mood changes
Rare or Very Rare
- Abnormal hepatic function tests
- Acute myocardial infarction
- Anaphylaxis
- Anaphylaxis
- Angioedema
- Angioedema
- Cerebrovascular accident
- Depression
- Depression
- Ectopic pregnancy
- Eosinophilic pneumonia
- Erythema multiforme
- Erythema nodosum
- Galactorrhea not associated with childbirth
- Gallbladder obstruction
- Hepatitis
- Hypersensitivity drug reaction
- Hypertension
- Hypertension
- Idiopathic intracranial hypertension
- Jaundice
- Malignant neoplasm of the ovary
- Menorrhagia
- Migration of implant
- Obstructive hyperbilirubinemia
- Obstructive hyperbilirubinemia
- Optic neuritis
- Ovarian cyst
- Ovarian cyst
- Pancreatitis
- Pruritus of skin
- Pulmonary thromboembolism
- Pulmonary thromboembolism
- Retinal thrombosis
- Skin rash
- Thromboembolic disorder
- Thrombophlebitis
- Thrombophlebitis
- Thrombotic disorder
More Frequent
- Acute abdominal pain
- Appetite changes
- Back pain
- Edema
- Edema
- Fatigue
- General weakness
- Headache disorder
- Headache disorder
- Injection site sequelae
- Mastalgia
- Myalgia
- Vaginitis
- Vaginitis
- Weight gain
- Weight loss
- Weight loss
Less Frequent
- Acne vulgaris
- Amenorrhea
- Back pain
- Cervical discharge
- Diarrhea
- Dizziness
- Dizziness
- Drowsy
- Dysmenorrhea
- Dyspepsia
- Ectropion of cervix
- Flu-like symptoms
- Hypertonia
- Implant site reaction
- Menstrual disorder
- Nausea
- Palpitations
- Pharyngitis
- Pruritus of skin
- Vaginal discharge
- Vaginal discharge
Rare or Very Rare
- Acne vulgaris
- Alopecia
- Alopecia
- Amenorrhea
- Body fluid retention
- Body fluid retention
- Cervical discharge
- Chest discomfort
- Chloasma
- Chloasma
- Constipation
- Constipation
- Cystitis
- Drowsy
- Dysuria
- Ectropion of cervix
- Fatigue
- Fever
- Fever
- Fibrocystic breast disease
- Flatulence
- Flushing
- Galactorrhea not associated with childbirth
- Genital organ pruritus
- Gynecomastia
- Hirsutism
- Hirsutism
- Hyperglycemia
- Insomnia
- Insomnia
- Irritability
- Libido changes
- Mastalgia
- Migraine
- Migraine
- Musculoskeletal pain
- Myalgia
- Nausea
- Nervousness
- Nervousness
- Pain
- Pain in extremities
- Paresthesia
- Rhinitis
- Seborrhea
- Sinusitis
- Skin rash
- Symptoms of anxiety
- Urinary incontinence
- Urinary tract infection
- Urticaria
- Urticaria
- Visual changes
- Vomiting
- Weight gain
Precautions
No enhanced messaging available.
No enhanced messaging available.
Progesterone is used to support embryo implantation and maintain pregnancy as a component of assisted reproductive technology (ART) treatment in infertile women. Such use is associated with increased ongoing pregnancy rates.
Although progestins have been used beginning in the first trimester of pregnancy to prevent habitual abortion or to treat threatened abortion, there is no adequate evidence from well-controlled studies to substantiate the efficacy of progestins for these uses; however, there is evidence of potential adverse effects on the fetus when these drugs are administered during the first 4 months of pregnancy. In addition, in most women, the cause of abortion is a defective ovum, which progestins could not be expected to influence. Because of their uterine-relaxant effects, progestins may delay spontaneous abortion of fertilized defective ova. Masculinization of the female fetus has reportedly occurred when progestins were used during pregnancy. Clitoral hypertrophy has been reported in a few female neonates born to women who had received medroxyprogesterone during pregnancy. An association between intrauterine exposure to female sex hormones and congenital anomalies, including cardiovascular and limb defects, has been suggested. (See Cautions: Pregnancy, Fertility, and Lactation, in Estrogen-Progestin Combinations 68:12.) Use of progestins generally is not recommended during the first 4 months of pregnancy.
Progesterone should not be used to induce withdrawal bleeding as a test for pregnancy.
Progestins are reportedly distributed into milk. The manufacturers warn that the possible effects of progestins in milk on nursing infants have not been determined.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Abnormal uterine bleeding due to hormonal imbalance | ||
| N92.4 | ICD10CM | Excessive bleeding in the premenopausal period |
| N92.5 | ICD10CM | Other specified irregular menstruation |
| N92.6 | ICD10CM | Irregular menstruation, unspecified |
| N93.8 | ICD10CM | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | ICD10CM | Abnormal uterine and vaginal bleeding, unspecified |
| N95.0 | ICD10CM | Postmenopausal bleeding |
| Amenorrhea secondary to ovarian dysfunction | ||
| E28.8 | ICD10CM | Other ovarian dysfunction |
| E28.9 | ICD10CM | Ovarian dysfunction, unspecified |
| N91.0 | ICD10CM | Primary amenorrhea |
| N91.1 | ICD10CM | Secondary amenorrhea |
| N91.2 | ICD10CM | Amenorrhea, unspecified |
| Corpus luteum insufficiency syndrome | ||
| E28.39 | ICD10CM | Other primary ovarian failure |
| E28.8 | ICD10CM | Other ovarian dysfunction |
| Secondary amenorrhea | ||
| N91.1 | ICD10CM | Secondary amenorrhea |
| N91.2 | ICD10CM | Amenorrhea, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.